Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
Year: 2022
Type: article
Study design: Observational Study
Abstract: Acquired resistance to BRAF/MEK-targeted therapy occurs in the majority of melanoma patients that harbor BRAF mutated tumors, leading to relapse or progression and the underlying mechanism is unclear in many cases. Using multiplex immunohistochemistry and spatial imaging analysis of paired tumor sections obtained from 11 melanoma patients prior to BRAF/MEK-targeted therapy and when the disease progressed on therapy, we observed a significant increase of tumor cellularity in the progressed tumors and the close association of SOX10+ melanoma cells with CD8+ T cells negatively correlated with patient’s progression-free survival (PFS). In the TCGA-melanoma dataset (n = 445), tumor cellularity exhibited additive prognostic value in the immune score signature to predict overall survival in patients with early-stage melanoma. Moreover, tumor cellularity prognoses OS independent of immune score in patients with late-stage melanoma.
Source: npj Precision Oncology
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,390
Awards: G1156645799, G1188393146, G1388609297, G2006259475, Leica Bond RX, G283432789, G3152736877, New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors, G359867969, G4513176822, G526617753, G5853943267, G6297262231, G6860057478, G819342005, VOLT (Vanderbilt Oncology Training Program), G9000081609, Vanderbilt Clinical Oncology Research Career Development Award, G9000130502, Cancer Center Support Grant, Cancer Center Support Grant
OpenAlex ID: W4205955455